If there's a provision in the contract for the industry to provide notice to the province when they're going to shut down production or slow down production or are not going to be able to provide drugs, that question needs to be answered by the provinces and territories. They have the contract. I do not. Our role has been to provide the support to the provinces and territories in identifying the other companies in Canada that they can go to. At the same time, we have a process in place within Health Canada as a regulator to be able to move very quickly on approving drugs in Canada, which may be a need for each jurisdiction.
A lot of work has gone into this process. I will have Paul Glover elaborate a bit more on that.